In general terms, I most likely would not recommend adjuvant capecitabine in a patient with completely resected, stage IA, mismatch-repair deficient cholangiocarcinoma. My justifications for this are as follows. First, the BILCAP study showed at best a marginal effectiveness of adjuvant capecitabine...